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A B S T R A C T
Background
Staphylococcus aureus permanently colonizes the vestibulum nasi of one-fifth of the human
population, which is a risk factor for autoinfection. The precise mechanisms whereby S. aureus
colonizes the nose are still unknown. The staphylococcal cell-wall protein clumping factor B
(ClfB) promotes adhesion to squamous epithelial cells in vitro and might be a physiologically
relevant colonization factor.
Methods and Findings
We define the role of the staphylococcal cytokeratin-binding protein ClfB in the colonization
process by artificial inoculation of human volunteers with a wild-type strain and its single locus
ClfB knock-out mutant. The wild-type strain adhered to immobilized recombinant human
cytokeratin 10 (CK10) in a dose-dependent manner, whereas the ClfB mutant did not. The
wild-type strain, when grown to the stationary phase in a poor growth medium, adhered better
to CK10, than when the same strain was grown in a nutrient-rich environment. Nasal cultures
show that the mutant strain is eliminated from the nares significantly faster than the wild-type
strain, with a median of 3 6 1 d versus 7 6 4 d (p¼ 0.006). Furthermore, the wild-type strain
was still present in the nares of 3/16 volunteers at the end of follow-up, and the mutant strain
was not.
Conclusions
The human colonization model, in combination with in vitro data, shows that the ClfB
protein is a major determinant of nasal-persistent S. aureus carriage and is a candidate target
molecule for decolonization strategies.
The Editors’ Summary of this article follows the references.
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Introduction
Staphylococcus aureus remains one of the prime human
bacterial pathogens, associated with significant morbidity and
mortality worldwide. The combination of an increasing
number of antimicrobials to which this pathogen has become
resistant and the lack of an effective vaccine underscores that
alternatives to combating S. aureus disease are urgently
required. In addition, community-acquired infections with
methicillin-resistant S. aureus (MRSA) are rising steeply [1,2].
Approximately 80% of invasive S. aureus infections are
autologous [3,4] in that they are caused by strains carried in
the nose by the patient prior to illness. Approximately 20%
of the adult population carries S. aureus in their nose
persistently, another 30% intermittently, whereas 50% are
non-carriers [5].
Persistent nasal carriers of S. aureus have an increased risk
of infection. Therefore, discovering strategies that prevent
nasal colonization of S. aureus in patients at risk of (auto)-
infection is attracting increasing attention. Intervening in S.
aureus colonization, however, requires the identification of
human and bacterial factors that are important in the process
[6,7].
Nasal colonization by S. aureus is likely to be facilitated by
its surface structures. These range from peptidoglycan
molecules and cell-wall teichoic acids to a wide variety of
proteins belonging to the family of microbial surface
components recognizing adhesive matrix molecules
(MSCRAMMs) [8,9]. The MSCRAMM clumping factor B (ClfB)
was recently identified as a major determinant of nasal
colonization of the mouse [10,11]. ClfB binds to human-type I
cytokeratin 10 (CK10), which is expressed on squamous
epithelial cells [12]. In addition, it was shown that anti-ClfB
antibodies could actively and passively protect mice from
staphylococcal colonization in the nose [13].
However, experiments to prove causal involvement of
bacterial factors in maintaining the colonized state were
performed in vitro or in animal models of questionable
relevance to the human situation [6,14,15]. None of the
animal species used in model experiments are natural nasal
carriers of S. aureus. Other studies relied on indirect clinical
or microbiological observations to define the involvement of
bacterial determinants in colonization and disease in humans
[16]. To our knowledge, in vivo experiments on the relevance
of bacterial factors required for S. aureus nasal colonization in
humans have not been performed thus far.
Although animal models may help define the molecular
mechanisms leading to colonization of the nose, a human
model of colonization will probably be most appropriate
[17,18]. Such an experimental model is essential in the design
of new strategies to prevent infection. This is important since
recent trials with topical antibiotics showed little to no
preventive effect on the rate of nosocomial S. aureus infection,
due to the poor efficacy of this type of treatment [19–21].
The present study investigates the survival of two different
S. aureus strains in a novel human nasal colonization model.
We used an S. aureus strain (8325–4) expressing ClfB and its
isogenic knockout, deficient in ClfB (DU5997). It was
hypothesized that ClfB is essential for adherence to the nasal
mucosa, hence absence of this factor would lead to a
significant reduction in S. aureus survival in the human nose.
Furthermore, we performed in vitro testing to demonstrate
that the S. aureus cells growing under in vivo–like conditions
can express ClfB and that these bacteria adhere to immobi-
lized CK10.
Materials and Methods
Study Population
Sixteen healthy volunteers (six males and ten females,
median age 32 y [range 19–51 y]) were included in this study.
Prior to enrollment, potential participants received a medical
checkup. Volunteers with a medical history of diabetes
mellitus, renal insufficiency, chronic skin disease (eczema or
psoriasis), chronic obstructive lung disease, disease of the
heart valve, immune deficiency, or recent antibiotic use were
excluded. Volunteers in close contact with individuals suffer-
ing from the afflictions mentioned above were excluded as
well. Informed consent was obtained. Participants were
notified of the fact that a dedicated infectious disease
physician would be on call for the entire study period.
Ethical Clearance
The study protocol was approved by the Medical Ethical
Committee of Erasmus MC (MEC 156.137/1996/186). Permis-
sion to inoculate volunteers with genetically modified S.
aureus strains was obtained from the Dutch authorities (Dutch
Committee on Genetic Modification [COGEM] protocols
BGGO 03/02.13 and CGM/040224–04).
S. aureus Strains
Strains 8325–4 (wild-type) and DU5997 (mutant) were used
for artificial nasal colonization of the human volunteers. The
genome sequence of the original 8325 strain is available at
http://www.genome.ou.edu. The 8325–4 strain differs from
8325 by the absence of three prophages [22]; 8325–4 has a
defect in the stationary-phase sigma factor (SigB) [23]. This
strain is therefore unlikely to colonize and persist as well as
8325-4 wild-type strain (WT) or DU5997 (mutant strain) and
thus facilitated a safe inoculation protocol for humans.
DU5997 is a ClfB mutant of S. aureus 8325–4 with a
promoter-less tetK gene (encoding low-level tetracycline
resistance) inserted in the clfB gene, as described previously
[24]. For comparative growth experiments, we additionally
used the S. aureus strain SH1000, a derivative of strain 8325–4,
which expresses wild-type levels of SigB [25].
Growth Experiment
To reflect the in vivo situation, bacterial strains were grown
in RPMI 1640 (Sigma), a minimal medium which is limited in
iron. Strains were also grown in tryptic soy broth (TSB).
Starter cultures were diluted in 60 ml of RPMI or TSB to an
OD600 of 0.1 and grown at 37 8C with shaking (200 rpm) and
absorbance at 600 nm monitored for 32 h (RPMI) or 24 h
(TSB) using a spectrophotometer.
Study Design: Artificial Inoculation Protocol
From all enrolled volunteers, we obtained two nasal
cultures 1 wk apart before artificial inoculation in order to
differentiate between persistent, intermittent, and non-
carriers, as described previously (Nouwen et al. [26]). To be
classified as a persistent carrier, both nasal cultures needed to
be positive with a S. aureus.. In case of one positive culture, the
volunteer was classified as an intermittent carrier. For non-
carriers, all cultures needed to be negative. Figure 1 illustrates
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the design of the study. Decolonization treatment was started
for all volunteers (nasal mupirocin twice daily for 5 d in
combination with once-daily washing with chlorhexidine-
containing soap for 5 d [Hibiscrub; Regent Medical]). Five
weeks after mupirocin and chlorhexidine treatment, nostrils
were cultured again to assess colonization status, and
experimental nasal inoculation was performed.
The two inoculation strains, 8325–4 and DU5997 (ClfB),
were cultured separately to log phase in TSB. A mixture was
prepared immediately prior to inoculation. In one nostril, 23
107 cfu of the 8325–4/DU5997 mixture in a 1:1 ratio was
applied, whereas in the contralateral nostril, 1 3 107 cfu of
either the 8325–4 or the DU5997 were installed. The nostrils
of volunteers were randomized as follows: first, the left or
right nostril was randomized to receive the inoculation mix
by drawing a sealed envelope. Second, another envelope was
drawn that contained instructions as to which single strain
(8325-4 or DU5997) should be inoculated in the contralateral
nostril. Thus, all 16 subjects had one nostril inoculated with
the mixed culture, and half had the contralateral nostril
inoculated with 8325–4 and the other half with DU5997.
Randomization was stratified by carriage status.
This design allowed for the assessment of the survival of
both strains, depending on two different inoculation proto-
cols. The inoculation was performed in a blinded fashion to
prevent bias in reading the growth results of the nasal
cultures. Follow-up cultures were performed on day 1, 2, 3, 4,
7, 14, 21, and 28 after inoculation (Figure 1).
SDS-PAGE, Western Immunoblotting, and Zymography
S. aureus cells were suspended to an OD600 of 40 in 30%
raffinose plus 20 mM MgCl2 in a final volume of 100 ll. To
each sample, 12-ll lysostaphin (2 mg/ml) and 8-ll protease
inhibitors (Complete cocktail; Boehringer Mannheim) were
added, and the suspension was incubated at 37 8C for 20 min.
Protoplasts were removed by centrifugation at 12,000g for 10
min. Supernatants containing wall-associated proteins were
boiled for 5 min in an equal volume of final sample buffer
(0.125 M Tris-HCl [pH 6.8], 4% [w/v] SDS, 20% [v/v] glycerol,
10% [v/v] b-mercaptoethanol, and 0.002% [w/v] bromophenol
blue). SDS-PAGE was performed by standard methods.
Proteins were electrophoretically transferred to PVDF West-
ern blotting membranes (Boehringer Mannheim) by the wet
system (Bio-Rad). Membranes were incubated overnight at 4
8C in 10% blocking reagent (Marvel milk powder). Primary
anti-ClfB A region antibody was used at a dilution of 1:5,000
for a 1-h incubation at room temperature. Protein A–
conjugated horseradish peroxidase (Sigma, a 1 mg/ml stock
diluted 1:500) was used to detect bound antibody by
incubation for 1 h at room temperature. Membranes were
developed using LumiGLO chemiluminescent substrate (New
England BioLabs), according to manufacturer’s instructions
and exposed to X-ray film.
Figure 1. Study Design
First, the left or right nostril was randomized to receive the inoculation mix, containing strains 8325-4 (WT) and DU5997 (mutant strain). Second, the
contralateral nostril was randomized to receive either the naturally occurring (‘‘WT’’ in figure) or mutant strain.
doi:10.1371/journal.pmed.0050017.g001
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Adherence of Bacterial Cells to Immobilized Recombinant
Human Cytokeratin 10
Adherence of S. aureus to immobilized recombinant human
cytokeratin 10 (rMK10) was performed as follows. Nunc-
Immuno MaxiSorb microtitre plates were coated with rMK10
in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3 [pH
9.6]) and incubated overnight at 4 8C. Bovine serum albumin
(5 mg/ml) was added, and the plates were incubated for 2 h at
37 8C. The plates were washed three times with PBS. A
bacterial cell suspension (OD600¼ 1.0 in PBS) was added (100
ll/well), and the plates were incubated for 1.5 h at 37 8C.
Plates were washed three times with PBS; bound cells were
fixed with formaldehyde (25% v/v) for 30 min and then
stained with Crystal Violet (0.5% v/v, 100 ll/well) for 1 min.
After three washes with PBS, acetic acid (5% v/v) was added
(100 ll/well), and cells were incubated for 10 min at room
temperature. The absorbance was measured at 570 nm in an
ELISA plate reader (Labsystems Multiskan Plus).
Microbiological Procedures
Nasal specimens were obtained with sterile cotton swabs
(Tran swab; Medical Wire & Equipment) from each nostril
separately. Swabs were processed immediately by vortexing
vigorously in Stuart’s medium. Dilutions of this medium were
inoculated on phenol red-mannitol salt agar (PHMA) and in
phenol red-mannitol salt broth (PHMB) according to pre-
viously published protocols for quantitative carriage assess-
ment [18,26]. All positive postinoculation cultures for S.
aureus were screened for tetracycline resistance, by plating on
media with and without tetracycline, to assess the presence of
tetracycline-resistant S. aureus strains in the endogenous nasal
flora of the participant. The DU5997 S. aureus strain has low-
level tetracycline resistance (minimal inhibitory concentra-
tion: 2 lg/ml). Technicians reading the agar plates were
unaware what strains were inoculated in the volunteers
(blinded assessment).
Bacterial Genotyping
Testing for tetracycline resistance was performed by disk
diffusion. Resistance was verified by PCR with specific
primers spanning the insertion site of the tetracycline
resistance cassette. Furthermore, two random isolates per
culture (either resistant or sensitive to tetracycline) were
genotyped by pulsed-field gel electrophoresis (PFGE) (CHEF
Mapper; Biorad). DNA within the plugs was digested using 20
U SmaI (Roche Molecular Diagnostics) during 4 h at 25 8C in
SuRe-cut buffer. The electrophoresis protocol was performed
at 6 V/cm and 14 8C using 0.53 TBE buffer (Biorad). The
program consisted of two blocks: 10 h at 608/608 angles with
a switch time of 5–15 s, followed by 10 h at 608/608 angles and
a switch time of 15–45 s. Strains were considered to be
clonally related if their PFGE fingerprints did not differ by
more than three bands [27].
Anti-ClfB ELISA
The working volume of serum for the ELISA was 100 ll.
After each step, the microplates were washed three times with
phosphate-buffered saline (PBS; pH 7.4) containing 0.1% v/v
Tween 20. The microplates were coated with recombinant
ClfB in 50 mM sodium carbonate (pH 9.5) overnight at 4 8C.
Blocking was performed with 5% (w/v) bovine serum albumin
in PBS for 2 h at 37 8C and washing for three times with PBS.
Serum of the volunteers was then applied and incubated for 1
h at room temperature with shaking. Dilute (1:10,000)
horseradish peroxidase conjugated to rabbit anti-human
antibodies (Dako) was then added to the wells, and the
incubation was continued for 1 h at room temperature. The
reaction was developed by the addition of tetramethylbenzi-
dine and stopped by adding H2SO4. The reaction was
measured at 450 nm in an ELISA plate reader (Bio-Rad).
Sample-Size Calculation
An earlier inoculation study showed that after artificial
inoculation, more than half of those inoculated still carried
the inoculating strain at 1-mo follow-up [18]. We estimated
that at the end of follow-up, the 8325–4 strain would still be
present in 50% of the inoculated volunteers, and the DU5997
strain in 10%. With a confidence level of 95% and a power of
80%, we would need to inoculate both the 8325–4 strain and
the DU5997 strain in at least 15 healthy volunteers.
Statistics
The primary outcome measurement was the survival time
of both the 8325–4 and DU5997 strain per individual, and
analyzed by Kaplan-Meier survival analysis (log-rank test).
The survival time was defined as the number of days until the
last positive culture. S. aureus strains still present at the end of
follow-up were censored. The mean numbers of 8325–4
versus DU5997 S. aureus cfu were compared by two-way
ANOVA, after log transformation of the number of cfu.
Other comparisons of means were performed by t-test, Mann-
Whitney U test, or one-way ANOVA, where appropriate.
Nonparametric correlations were estimated for ClfB anti-
body titer and time to S. aureus clearance from the nose. p-
Values, two-tailed, below 0.05 were considered statistically
significant. All statistical analyses were performed with SPSS
11.5 for Windows software (SPSS). Means and medians are
given with their standard deviations or interquartile range.
Results
Nasal Carriage Status before Inoculation
None of the volunteers included in the present study
encountered adverse effects, and all adhered to the study
protocol for the duration of the experiment. At the start of
the protocol, the carriage status was assessed: there were six
persistent carriers, two intermittent carriers, and eight non-
carriers. All volunteers received mupirocin nasal ointment 5
wk before inoculation (Figure 1). Five volunteers still carried
low levels of S. aureus in their noses after mupirocin
treatment, just before inoculation (median: 1 cfu/ml). The
endogenous S. aureus strains of the volunteers who were
carriers had distinct PFGE fingerprints compared to the test
strains (unpublished data).
The DU5997 Strain Has the Same Fitness as the 8325–4
Strain
We compared the growth of strain 8325–4 with SH1000
(which has a fully functional SigB), and with DU5997 (which is
defective in ClfB). Growth was carried out in a medium
reflective of growth conditions in vivo. The results show that
bacteria grew more slowly and to a much lower optical density
in stationary phase in RPMI as compared to TSB. Doubling
times for 8325–4 were 108 min in RPMI and 40 min in TSB. In
RPMI, the growth rates and yields of 8325–4 and DU5997 were
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indistinguishable, whereas SH1000 grew slightly faster (dou-
bling time 96 min) and to a higher density (Figure 2A).
ClfB Expression-Dependent Adherence to Cytokeratin 10
Expression of ClfB by RPMI- and TSB-grown bacteria was
compared. Previously, it was shown that ClfB protein was not
detectable on 8325–4 cells from the stationary phase of
growth in rich media, and this was confirmed here (Figure 2B)
[28]. In contrast, intact ClfB was present at the same level in
RPMI-grown SH1000 and 8325–4 during all phases of growth,
including late stationary phase (Figure 2B).
Bacterial cells grown to mid-exponential phase were tested
for their ability to adhere to immobilized CK10 (Figure 3).
Strain 8325–4 grown in TSB adhered more strongly to CK10
than 8325–4 grown in RPMI, despite degradation of some
ClfB molecules to the nonfunctional form lacking domain N1
[28]. DU5997, which is completely defective in ClfB expres-
sion, adhered poorly, indicating that the adherence of RPMI-
grown bacteria to CK10 is dependent on the presence of ClfB.
In contrast to exponential phase cells, 8325–4 grown to
stationary phase in TSB was defective in adherence (Figure 3),
which is consistent with the lack of ClfB shown in Figure 2D.
Strain 8325–4 grown to stationary phase in RPMI adhered
more strongly to CK10 than the equivalent number of cells
from exponential phase, whereas the DU5997 bound poorly.
Strain 8325–4 Persists in the Nose, DU5997 Does Not
Upon inoculation of 8325–4 and DU5997 ClfB cells, the
majority of the volunteers (14/16) did not harbor the DU5997
strain after day 4, whereas fewer volunteers (7/16) lacked the
8325–4 strain after this stage. After 2 wk, all volunteers had
eliminated the DU5997 strain, whereas the 8325–4 strain was
still present in three volunteers after 28 d, at the end of
follow-up. These three volunteers were found to be persistent
or intermittent nasal carriers during the preinoculation
screening.
The overall median survival time of the 8325–4 strain was
significantly higher than the DU5997 strain: a median of 7.0
(95% confidence interval [CI], 64 d; interquartile range: 2–21
d) compared to 3 (95% CI, 61 d; interquartile range: 2–4 d;
log-rank: p¼ 0.006; Figure 4A). The viable counts of S. aureus
after inoculation were always higher for the 8325–4 strain
(Figure 4C), but not significantly. Inoculated S. aureus cells
could be cultured for a longer mean follow-up period from
intermittent carriers (18.3 6 12.1 d) than from persistent (7.0
6 8.6 d) or non-carriers (5.4 6 6.3 d; one-way ANOVA: p ¼
0.025). None of the volunteers used antibiotics during the
follow-up period. Identification of the inoculation strains was
confirmed by tetracycline susceptibility testing, PFGE, and
PCR analysis of the clfB locus.
Analyzing the survival within the nostril in which the mix
was inoculated also shows that the 8325–4 strain survives
significantly longer: a median of 4.0 (95% CI, 6 1 d;
interquartile range: 2–7 d) compared to 3.0 (95% CI, 61 d;
interquartile range: 1–3 d; log rank: p ¼ 0.033; Figure 4B).
Comparing the survival of the 8325–4 strain inoculated
singularly in eight nostrils versus the DU5997 strain inocu-
Figure 2. ClfB Expression Experiments
(A) Bacterial growth and ClfB expression in RPMI. Strains 8325–4, DU5997, and SH1000 were grown in RPMI, and samples were taken at regular intervals
to monitor growth.
(B) Samples taken at early exponential, early stationary, and late stationary phases of growth were analyzed by Western immunoblotting. Lanes 1, 2, and
3 show ClfB expression from strain 8325–4 at early exponential, early stationary, and late stationary growth phases, respectively. Lanes 4, 5, and 6 show
ClfB expression from strain DU5997 at early exponential, early stationary, and late stationary growth phases, respectively. Lanes 7, 8, and 9 show ClfB
expression from SH1000 at early exponential, early stationary, and late stationary growth phases, respectively.
(C) Bacterial growth and ClfB expression in TSB. Strain 8325–4 was grown in TSB, and samples were taken at regular intervals to monitor growth.
(D) Western immunoblotting was carried out to detect ClfB expression at early exponential, early stationary, and late stationary phases of growth. Lanes
1, 2, and 3 show ClfB expression from strain 8325–4 grown in TSB at early exponential, early stationary, and late stationary growth phases, respectively.
doi:10.1371/journal.pmed.0050017.g002
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lated in eight other volunteers, also showed a longer survival
for 8325–4, but this did not reach statistical significance
(unpublished data). In this experiment, we also evaluated
whether strains crossed over to the contralateral nostril,
irrespective of bacterial load and strain displacement. In two
instances, there was crossover from the DU5997 strain from
the mix to the contralateral nostril where only 8325–4 strain
was inoculated (only on the first day after artificial
inoculation). The 8325–4 strain from the mix crossed over
in six volunteers to the contralateral nostril where only the
DU5997 was inoculated, occurring as of day 1 up to day 28 of
follow-up.
Dynamics in ClfB Antibody Response
To assess the role of the anti-ClfB antibody response in the
survival of the inoculating strains, we performed anti-ClfB
ELISA. The anti-ClfB antibody levels in volunteers did not
change during the 4 wk following inoculation. However,
volunteers who were carriers of S. aureus had a higher anti-
ClfB antibody level: 2.0 6 0.7 (extinction), than those who
were non-carriers: 1.3 6 0.7 (Mann-Whitney U: p ¼ 0.093).
Those volunteers who were still carrying the 8325–4 strain
after 28 d also had a higher anti-ClfB antibody titer compared
to those who were free of S. aureus: 2.4 6 0.4 versus 1.5 6 0.7
(Mann-Whitney U: p¼0.069). Finally, there was no correlation
between the anti-ClfB antibody titer and the time needed to
eradicate S. aureus from the nose (unpublished data).
Discussion
We report here the first study, to our knowledge, of healthy
human volunteers being coinoculated with an S. aureus 8325–
4 strain and an isogenic mutant defective in the MSCRAMM
ClfB (DU5997). We show that ClfB is an important factor for
establishing human nasal colonization by S. aureus, as the
ClfB mutant (DU5997) was not able to survive in the human
nose after 2 wk. In contrast, the 8325–4 strain was still present
at the end of follow-up in three volunteers.
Because we performed two different inoculation protocols
within each volunteer, crossover of strains to the contrala-
teral nostril complicated the analysis of this study. The 8325–
4 strain from the mix crossed over in six volunteers, whereas
the DU5997 strain only crossed over in two instances.
Furthermore, the 8325–4 strain showed this phenomenon
up to the last day of follow-up. The DU5997 only crossed over
on the first day of follow up and never after. These findings
highlight the complexity of interpretation of in vivo studies
but strongly suggest that 8325–4 is better able to colonize
than DU5997.
The results of our study regarding the number of
volunteers still colonized after 1 mo are different than the
assumptions of our sample-size calculation. At the end of
follow-up, only 19% of the volunteers carried the 8325–4
strain, not 50%. This low carriage may be due to the fact that
we inoculated only one type of S. aureus strain and not a mix
with different clones as performed by Nouwen et al. [18]. In
addition, the 8325–4 strain has been propagated in the
laboratory for a long period and might have lost most of its
capacity to effectively colonize humans. On the other hand,
the survival of the ClfB mutant (DU5997) was lower than
estimated (0% at day 28, instead of 10%), illustrating the
crucial role of ClfB in adherence to the nasal mucosa.
Interestingly, 8325–4 grown to stationary phase in a
nutrient-deficient medium, comparable to that of the nasal
niche, adhered to rK10, whereas the same strain grown in a
rich medium did not. Thus, it seems plausible that ClfB is
expressed in all S. aureus growth stages in the nose, a relatively
nutrient-deficient environment. Expression of the clfB gene
directly in the growth environment of the human nose has
been demonstrated previously [10]. Furthermore, the ClfB
mutant grown in nutrient-deficient media was unable to
Figure 3. S. aureus Adherence to Recombinant Cytokeratin 10 in Different Growth Stages
Data are epresentative of three independent experiments. Bars represent standard deviation.
(A) Adherence of bacterial cells in exponential phase of growth to rMK10. Strain 8325–4 was grown to exponential phase in RPMI or TSB, and its ability
to bind rMK10 was compared to DU5997 grown in RPMI.
(B) Adherence of bacterial cells in stationary phase of growth to rMK10. Strain 8325–4 was grown to stationary phase in RPMI or TSB, and its ability to
bind rMK10 was compared to DU5997 grown in RPMI.
doi:10.1371/journal.pmed.0050017.g003
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adhere to immobilized CK10. These in vitro study results
support our in vivo findings.
Other in vitro studies showed ClfB-deficient mutants could
still adhere to nasal epithelial cells [10]. Even though these
experiments were not performed in nutrient-deficient media,
it is unlikely that ClfB is the sole determinant of nasal
colonization. Other S. aureus surface factors, including
capsular polysaccharides, teichoic acid, and iron-responsive
surface determinant protein (IsdA), also promote adherence
to the nasal mucosal surfaces [15,29,30]. These studies were
performed either in vitro or in animals. Clearly, S. aureus
adherence to and colonization of the epithelium in the nares
is complex and multifactorial. Only the direct application of
viable, genetically modified S. aureus cells in their natural
niche, the human vestibulum nasi, will allow functional
characterization of both human and microbial factors
required for colonization.
Regarding the complexity of the human factor: in this
study. the anti-ClfB antibody response was also assessed. No
rise in the anti-ClfB response after the artificial colonization
was documented. This may be explained by the fact that
8325–4 has a defect in the stationary phase SigB and is
therefore considered less virulent, and may therefore be less
‘‘immunogenic.’’ We did find that, in general, S. aureus
carriers had higher anti-ClfB levels than non-carriers. This
is concordant with the results of Dryla et al. [31], who found
significantly higher IgG levels in S. aureus nasal carriers.
Effective intervention in S. aureus colonization for the
prevention of subsequent infection requires the identifica-
tion of human and bacterial factors important in establishing
nasal colonization [6,7]. This study of a 8325–4 strain and an
isogenic ClfB null mutant revealed the relevance of the
staphylococcal adhesin ClfB in the colonization of the human
nose and demonstrates that ClfB is a potential target for S.
aureus decolonization strategies.
Figure 4. Survival in the Nose of the Wild-Type Strain versus the Mutant Strain
(A) Kaplan-Meier survival curve of the 8325–4 S. aureus (solid line) and its ClfBmutant (DU5997) strain (dashed line) in human nose (last cultured strain
in either nostril). All cells of the mutant strain were eliminated after a period of 14 d, which is significantly faster than the elimination rate for the 8325–4
S. aureus strain.
(B) Kaplan-Meier survival curve of the 8325–4 S. aureus (WT) and ClfB mutant (DU5997; dashed line) that were inoculated together as a mix in one
nostril.
(C) Number of cfu of 8325–4 and DU5997 in follow-up samples.
doi:10.1371/journal.pmed.0050017.g004
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Limitations of This Study
A limitation of this study was the use of the 8325–4 strain.
As mentioned before, this strain has a defect in the stationary
phase SigB and is therefore unlikely to colonize and persist as
well as wild-type strains we would find in natural S. aureus
nasal carriers. We chose this strain because it facilitated a safe
inoculation protocol for humans and actually made this
experiment possible. A S. aureus strain from a natural carrier
with no major virulence factors, such as superantigens, would
be preferred for future artificial inoculation experiments.
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Editors’ Summary
Background. Staphylococcus aureus are common bacteria that normally
live on the skin. They also colonize the nostrils of about one in five adults
permanently and another one in three adults intermittently. Although
these bacteria usually coexist peacefully with their human carriers, they
can cause minor infections such as pimples and boils if they enter the
skin through a cut or a sore. They can also cause potentially life-
threatening infections such as blood poisoning and pneumonia. These
serious, invasive infections are often ‘‘autoinfections.’’ That is, they are
caused by strains of S. aureus that are present in the patient’s nose
before they become ill. Minor S. aureus infections can be treated without
antibiotics—by draining a boil, for example. Invasive infections are
usually treated with antibiotics such as flucloxacillin.
Why Was This Study Done? There is no effective vaccine against S.
aureus infections and these bacteria are becoming increasingly resistant
to flucloxacillin, methicillin, and other antibiotics. Worryingly, although
methicillin-resistant S. aureus (MRSA) infections occur most frequently
among people in health-care facilities who have weakened immune
systems, community-acquired MRSA infections among otherwise healthy
people are increasingly common. Consequently, new ways to avoid S.
aureus infections are urgently needed. Because persistent nasal carriers
of S. aureus have an increased risk of infection, one strategy might be to
prevent nasal colonization with S. aureus. How these bacteria colonize
the nose is poorly understood, but is likely to involve interactions
between molecules expressed on the surface of the bacteria and
molecules expressed on the surface of the cells lining the nostrils. In this
study, the researchers use a new human nasal colonization assay to
investigate the involvement of a bacterial surface protein called
clumping factor B (ClfB) in the survival of S. aureus in the human nose.
ClfB binds to cytokeratin 10, a protein expressed by cells lining the
human nose, and has been implicated in the colonization of mouse
noses by S. aureus.
What Did the Researchers Do and Find? The researchers introduced a
strain of S. aureus that made ClfB and an otherwise identical, mutant
strain that lacked ClfB into the nostrils of healthy human volunteers and
measured how long the two strains survived. For safety reasons, the S.
aureus strains used in this study have an additional defect that makes
them less likely to colonize and persist in the human nose than the
strains found in natural S. aureus carriers. Although both strains grew
equally well in the laboratory, the mutant strain was eliminated from
human noses much quicker than the strain that made ClfB. Mutant
bacteria lacking ClfB were cleared from the nostrils of all the volunteers
within two weeks, whereas the bacteria that made ClfB were still present
in some of the volunteers four weeks after their introduction. When the
researchers investigated how well the two strains stuck to a layer of
human cytokeratin 10 in a plastic dish, they found that the bacteria that
made ClfB stuck to the human protein but the mutant bacteria did not.
Furthermore, the strain with ClfB stuck particularly well to cytokeratin 10
when the bacteria had been grown in conditions where nutrients were
limiting, a situation that mimics bacterial growth in the human nose.
What Do These Findings Mean? These findings show that ClfB is an
important factor in the establishment of human nasal colonization by S.
aureus and suggest that ClfB might be a target for S. aureus
decolonization strategies. Furthermore, although ClfB is clearly important
in human nasal colonization by S. aureus, it is likely that additional
bacterial factors will also be involved in this process. The human nasal
colonization model used in this study may be useful in the identification
of these additional factors and also as a test bed for potential S. aureus
decolonization strategies.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050017.
 The MedlinePlus encyclopedia has a page on Staphylococcus aureus
and MRSA (in English and Spanish)
 The US Centers for Disease Control and Prevention provides
information on community-associated MRSA (in English and Spanish)
 The UK National Health Service’s health website (NHS Direct) provides
information about staphylococcal infections and about MRSA
 The UK Health Protection Agency provides information about
Staphylococcus aureus
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